Bayer: YAZ approved in Japan for the treatment of dysmenorrhea

28-Jul-2010 - Japan

Bayer Schering Pharma AG, Germany, and Bayer Yakuhin, Ltd., Japan, announced that the Japanese regulatory authorities have granted approval for YAZ® (3 mg drospirenone/20 mcg ethinyl estradiol) for the treatment of dysmenorrhea.

YAZ is available in the US, Europe, Latin America and the region Asia Pacific. In the US and several other countries in various regions, it is approved as an oral contraceptive as well as for the treatment of the symptoms of Premenstrual Dysphoric Disorder (PMDD) and/or moderate acne vulgaris in women desiring oral contraception.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances